Search

Your search keyword '"Mycophenolate sodium"' showing total 244 results

Search Constraints

Start Over You searched for: Descriptor "Mycophenolate sodium" Remove constraint Descriptor: "Mycophenolate sodium" Topic mycophenolic acid Remove constraint Topic: mycophenolic acid
244 results on '"Mycophenolate sodium"'

Search Results

1. Tolerability of mycophenolate sodium in renal transplant recipients.

2. Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients.

3. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.

4. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.

5. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.

6. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent.

7. Mycophenolic Acid

8. Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients

9. Validation of a simple HPLC method to quantify mycophenolic acid concentrations in human plasma

10. Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients.

11. Development and validation of an ultra-performance liquid chromatography mass spectrometry/mass spectrometry method for simultaneous quantification of total and free mycophenolic acid and its metabolites in human plasma

12. Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial

13. Prospective study of the changes in pharmacokinetics of immunosuppressive medications after laparoscopic sleeve gastrectomy

14. Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis

15. Systemic safety analysis of mycophenolate in Graves’ orbitopathy

16. Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN)

17. Investigation of the Association Between Total and Free Plasma and Saliva Mycophenolic Acid Concentrations Following Administration of Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients

18. The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis

19. Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post–Renal Transplant

20. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis

21. Pharmacokinetics of Enteric-Coated Mycophenolate Sodium Metabolites in Patients Over 60 Years Old Within the First Year After Renal Transplantation

22. A short overview on mycophenolic acid pharmacology and pharmacokinetics

23. The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients

24. Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus

25. Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial

26. Development of an Abbreviated Mycophenolic Acid Area Under the Time–Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations

27. Early Immunosuppressive Exposure of Enteric-Coated-Mycophenolate Sodium Plus Tacrolimus Associated with Acute Rejection in Expanded Criteria Donor Kidney Transplantation

28. Evaluation of Mycophenolic Acid Exposure Using a Limited Sampling Strategy in Renal Transplant Recipients.

29. Enteric-coated mycophenolate sodium in de novo and maintenance kidney-pancreas transplant recipients.

30. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study.

31. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease.

32. Complete remission of nephrotic syndrome and acute kidney injury in crescentic IgA nephropathy: Role of mycophenolate sodium.

33. Mycophenolate Sodium for Immunosuppressive Treatment in Uveitis.

34. Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium.

35. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience

36. Administration of enteric-coated mycophenolate sodium in children with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis

37. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial

38. Quantitative Determination of Mycophenolic Acid in Human Blood Plasma by High-Performance Liquid Chromatography with Tandem Mass-Spectrometric Detection

39. Количественное определение микофеноловой кислоты в плазме крови человека методом ВЭЖХ с тандемным масс-спектрометрическим детектированием

40. Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism

41. Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation

42. Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats

43. Mycophenolates: The latest modern and potent immunosuppressive drugs in adult kidney transplantation: What we should know about them?

44. Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease

45. Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients

46. Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium

47. Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis

48. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor–Free Renal Transplant Recipients

49. Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure

50. Improvement in Severe Mycophenolic Acid-associated Gastrointestinal Symptoms after Changing Enteric-coated Mycophenolate Sodium to Mizoribine in Renal Transplant Recipients: Two Case Reports

Catalog

Books, media, physical & digital resources